EndoCeutics, Inc. · Quebec City, PQ Canada
Company Description
View EndoCeutics, Inc. Locations On A US Map
This link will open in a new window
Ending breast cancer is top priority at EndoCeutics. The trial-phase biopharmaceutical company develops hormone therapies for treating and preventing breast cancer and endocrine-related disorders affecting postmenopausal women, as well as aging men. The company specializes in phase III clinical trials and commercialization of pharmaceuticals. Its leading product candidate, acolbifene, is a selective estrogen receptor modulator (SERM) that inhibits the stimulatory effect that estrogen (a female sex hormone) has on the growth of breast and uterine cancer. Other products include DHEA for use in treatment of postmenopausal women suffering from vaginal atrophy. To read the full description, subscribe now.
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!
Key EndoCeutics, Inc. Financials
| Company Type | Private Headquarters |
| Fiscal Year-End | December |
| Annual Sales (mil.) | $0.1 |
| Employees | 1 |
EndoCeutics, Inc. Executives
2 executives listed for EndoCeutics, Inc.'s Quebec City, PQ location.
| Title | Name & Bio | Contact |
| President, CEO, Chief Scientific Officer, and Director | Fernand Labrie | Network |
| CFO | Claude Doré | Network |
Competition
Competitive Landscape for EndoCeutics, Inc.
Demand often depends on the income of consumers or the profitability of business customers, because many technology products and services are expensive. The profitability of individual companies is driven by their ability to develop and market new products. Large companies often have advantages in access to capital and marketing. Small companies can compete successfully if they have expertise in a particular field of knowledge. The industry is capital-intensive: average annual revenue per worker is nearly $300,000. To read the full description, subscribe now.Top EndoCeutics, Inc. Competitors
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!
